Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Project description

Bioresorbable implant for in situ chemotherapeutics monitoring

Health condition monitoring involves the analysis of biological fluids including blood, serum, plasma and urine. However, under specific medical situations such as acute trauma or cancer treatment, there is a need to continuously record specific analytes as well as drug levels in vivo. To address this demand, the RESORB project funded by the European Innovation Council will develop a novel chemical sensing technology that employs bioresorbable materials. The system will be implanted in the body to monitor in real time various analytes as well as the levels of chemotherapeutic drugs in situ for approximately 2 months. The biodegradable nature of the implant avoids complications associated with its surgical removal and facilitates fine-tuning of drug dose administration for optimal clinical outcome.

Objective

We envision a radically new technology for in-vivo bioresorbable chemical sensing, where optical devices, power and light sources, synthetic receptors - made out of materials that completely dissolve with biologically benign byproducts in biofluids - will be developed and integrated together. The sensing system, the size of 1 EuroCent, will be coated by a long-lived biocompatible polymer designed with on-demand degradation, then implanted in the body to monitor in-vivo, in-situ, and in real-time a chemotherapeutic drug, doxorubicin, commonly used to treat cancer; the system is then fully and safely RESORBed once no more needed using an external temperature-trigger that initiates the dissolution of the protecting coating and, in turn, of the system, avoiding device-retrieval surgery that may cause tissue lesion/infection. The general objective is to demonstrate fabrication, operation (2 months) in-vivo and in real-time - then dissolution - of such a bioresorbable chemical sensing system for the detection of doxorubicin in an animal model. This will break a new ground in in-situ monitoring of chemotherapeutic drug enabling – for the first time – a fine tuning of the drug dose at the tumor site, increasing patient survival rate. Being aware of the project risks, we have broken down the general into different specific objectives, identified a set of Key Performance Indicators, alternative material synthesis/device fabrication techniques, mitigation measures to tackle major risks. The RESORB technology truly represents the foundation of a future technology for personalized medicine, enabling to address a number of medical issues for which continuous and localized monitoring of specific analytes (i.e. biomarkers and drugs) in-vivo for a prescribed time is of chief importance, e.g. acute trauma treatment, post-surgery sepsis, drug therapeutic profiling, and other, all examples for which ex-situ analysis of biofluids has proved to be not fully adequate for clinical needs.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

UNIVERSITA DI PISA
Net EU contribution
€ 721 250,00
Address
LUNGARNO PACINOTTI 43/44
56126 Pisa
Italy
Region
Centro (IT) Toscana Pisa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 721 250,00

Participants (4)

Partners (2)